Salvianolic acid C
Based on 6 publication(s) in Google Scholar
Salvianolic acid C is a noncompetitive Cytochrome P4502C8 (CYP2C8) inhibitor and a moderate mixed inhibitor of Cytochrome P45022J2 (CYP2J2), with Kis of 4.82 μM and 5.75 μM for CYP2C8 and CYP2J2, respectively.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.31%
- CAS No.: 115841-09-3
- Formule: C26H20O10
- Masse moléculaire:492.43
-
Stockage:
4°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Salvianolic acid C
More
Customer Validation & Images
-
WB
-
ELISA
-
In Vivo Efficacy Study
-
Flow Cytometry
-
Cell Imaging/Staining
Activité biologique
|
CYP2C8 4.82 μM (Ki) |
CYP2J2 5.75 μM (Ki) |
Salvianolic acid C is a noncompetitive CYP2C8 inhibitor and a moderate mixed inhibitor of CYP2J2, with Kis of 4.82, 5.75 μM for CYP2C8 and CYP2J2, respectively[1]. 1 and 5 μM Salvianolic acid C (SalC) could significantly inhibit the NO production induced by LPS. Salvianolic acid C decreases the expression of iNOS significantly. Salvianolic acid C inhibits LPS-induced TNF-α, IL-1β, IL-6 and IL-10 overproduction. Salvianolic acid C inhibits LPS-induced NF κB activation. Salvianolic acid C also increases the expression of Nrf2 and HO-1 in BV2 microglial cells[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 115841-09-3
-
Appearance Solid
-
Masse moléculaire 492.43
-
Formule C26H20O10
-
Color Light yellow to yellow
-
SMILES
OC1=C(O)C=CC(C[C@H](C(O)=O)OC(/C=C/C2=CC=C(O)C3=C2C=C(C4=CC(O)=C(O)C=C4)O3)=O)=C1
-
Structure Classification
-
Initial Source
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
4°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
Publications (6)
-
Journal Impact Factor
-
Most Recent
-
Autophagy
ESRRA-ATG5-Mediated mitophagy enhances arginine metabolism to alleviate diabetic kidney disease. [Abstract]2025 Dec 23:1-25. PMID: 41376268 -
J Clin Invest
YTHDF1 loss in dendritic cells potentiates radiation-induced antitumor immunity via STING-dependent type I IFN production. [Abstract]2024 Dec 2;134(23):e181612. PMID: 39325547
Salvianolic acid C purchased from MedChemExpress. Usage Cited in: J Clin Invest. 2024 Dec 2;134(23):e181612. [Abstract]
BMDCs from WT mice were treated with 20 μM Salvianolic acid C (SAC) for 24 hours, and the expression of cathepsins A and B was detected by Western blotting.
Salvianolic acid C purchased from MedChemExpress. Usage Cited in: J Clin Invest. 2024 Dec 2;134(23):e181612. [Abstract]
BMDCs from WT mice were pretreated with Salvianolic acid C (SAC) (20 μM) for 24 hours and then cocultured with 40 Gy–pretreated or nonirradiated B16-OZ cells for 8 hours. Purified CD11c+ cells were incubated for another 2 days, and the supernatants were collected to measure IFN-β.
Salvianolic acid C purchased from MedChemExpress. Usage Cited in: J Clin Invest. 2024 Dec 2;134(23):e181612. [Abstract]
B16-OVA tumor–bearing mice were treated with IR (20 Gy, 1 dose) and antigen-pulsed BMDCs from WT mice with or without Salvianolic acid C (SAC) treatment (twice weekly by i.t. injection).
-
Pharmaceuticals (Basel)
Doxorubicin-Induced Platelet Activation and Clearance Relieved by Salvianolic Acid Compound: Novel Mechanism and Potential Therapy for Chemotherapy-Associated Thrombosis and Thrombocytopenia. [Abstract]2022 Nov 22;15(12):1444. PMID: 36558895
Salvianolic acid C purchased from MedChemExpress. Usage Cited in: Pharmaceuticals (Basel). 2022 Nov 22;15(12):1444. [Abstract]
Dox increased human platelet phagocytosis by differentiated THP-1 macrophages. Platelets were stained with CMFDA and then co-incubated with differentiated THP-1 cells and 40 μg/mL Dox pretreated with or without Salvianolic acid C (SAC) (40 µM). THP-1 cells were washed to remove platelets and analyzed for CMFDA signal by flow cytometry.
Salvianolic acid C purchased from MedChemExpress. Usage Cited in: Pharmaceuticals (Basel). 2022 Nov 22;15(12):1444. [Abstract]
Salvianolic acid C (SAC) (20 μM) could ameliorate Dox induced cancer cell-platelet Interaction.
-
Int Immunopharmacol
Salvianolic acid C attenuates liver fibrosis and inhibites hepatic stellate cell activation by targeting FAP/TβRI/SMAD axis. [Abstract]2026 Apr 15:175:116400. PMID: 41740338 -
Int J Rheum Dis
Salvianolic acid C promotes osteogenic differentiation of bone marrow mesenchymal stem cells in osteoporotic rats through activation of AMPK/SIRT1 pathway. [Abstract]2023 Aug;26(8):1571-1578. PMID: 37318001 -
Solvant et solubilité
DMSO : 50 mg/mL (101.54 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (5.08 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (5.08 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureté et documentation
-
Fiche technique (275 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Xu MJ, et al. Inhibitory Effects of Danshen components on CYP2C8 and CYP2J2. Chem Biol Interact. 2018 Jun 1;289:15-22. [Content Brief]
[2]. Song J, et al. Activation of Nrf2 signaling by salvianolic acid C attenuates NF‑κB mediated inflammatory response both in vivo and in vitro. Int Immunopharmacol. 2018 Oct;63:299-310. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.0307 mL | 10.1537 mL | 20.3075 mL | 50.7686 mL |
| 5 mM | 0.4061 mL | 2.0307 mL | 4.0615 mL | 10.1537 mL | |
| 10 mM | 0.2031 mL | 1.0154 mL | 2.0307 mL | 5.0769 mL | |
| 15 mM | 0.1354 mL | 0.6769 mL | 1.3538 mL | 3.3846 mL | |
| 20 mM | 0.1015 mL | 0.5077 mL | 1.0154 mL | 2.5384 mL | |
| 25 mM | 0.0812 mL | 0.4061 mL | 0.8123 mL | 2.0307 mL | |
| 30 mM | 0.0677 mL | 0.3385 mL | 0.6769 mL | 1.6923 mL | |
| 40 mM | 0.0508 mL | 0.2538 mL | 0.5077 mL | 1.2692 mL | |
| 50 mM | 0.0406 mL | 0.2031 mL | 0.4061 mL | 1.0154 mL | |
| 60 mM | 0.0338 mL | 0.1692 mL | 0.3385 mL | 0.8461 mL | |
| 80 mM | 0.0254 mL | 0.1269 mL | 0.2538 mL | 0.6346 mL | |
| 100 mM | 0.0203 mL | 0.1015 mL | 0.2031 mL | 0.5077 mL |
Salvianolic acid C Related Classifications
HY-N0319 Related Classifications
Powered by Bioz